Patent GB-1347203-A (GB)
Title: Adenosine derivatives their preparation and compositions containing them
IPC: C07H19/16
Filed: 1972-03-28
Abstract: 1347203 N(6)-adenosine derivatives MERCK PATENT GmbH 28 March 1972 [10 April 1971 3 Feb 1972] 14446/72 Heading C2C Novel compounds of Formula I and their salts in which A is hydrogen, halogen, SR<SP>2</SP>, OR<SP>2</SP> N(R<SP>2</SP>) 2 , NH-N(R<SP>2</SP>) 2  or N 3 , R 1  is -CH 2 OH, an alkyl or cycloalkyl group of up to 6 C atoms, COOR<SP>2</SP>, furyl, tetrahydrofuryl, thienyl, a saturated or unsaturated 5- or 6-membered ring containing one or two nitrogen atoms, or a phenyl radical (optionally substituted one or more times by R<SP>2</SP>, OR<SP>2</SP>, N(R<SP>2</SP>) 2 , OAc, NHAc or nitro substituents or substituted with an alkylenedioxy group), R<SP>2</SP> is hydrogen or C 1-4  alkyl, Y is -CH 2 -, -(CH 2 ) 2 - or -(CH 2 ) 3 -, Ac is a C 1-6  carboxylic radical and Z is a bond, -CH 2 - or -(CH 2 ) 2 - and in which a double bond may be present at the position indicated by the dotted line are prepared by (1) reacting a compound of Formula II in which X is halogen, SR<SP>6</SP>, SOR<SP>6</SP> or SO 2 R<SP>6</SP>, where R<SP>6</SP> is C 1-6  alkyl, phenyl or benzyl, with an amine of general Formula III (2) treating a compound of Formula I which contains a solvolytically or hydrogenolytically removed group and in which A is hydrogen with a solvolysing or hydrogenolysing agent; (3) condensing an adenine derivative of Formula IV with D-ribose in the presence of a condensing agent, preferably polyphosphoric acid phenyl ester, (4) treating an adenosine derivative of Formula V in which An<SP>(-)</SP> is a monovalent equivalent of an anion with a base or (5) fermenting a D-riboseyielding nutrient medium which contains a compound IV with a micro-organism capable of forming D-ribose from the medium and linking the D-ribose formed with compound IV; the micro-organism being preferably Bacillus subtilis. A compound of Formula I may be treated with a nucleophilic agent to replace a substituent A by another substituent A and/or may be treated with an acid to form a physiologically acceptable salt. N(6) - (3 - phenyl - norcamphenyl-2)adenosine derivatives may be prepared by reacting a 2<SP>1</SP>,3<SP>1</SP>,5<SP>1</SP>-O-acetyl adenosine or an adenosine derivative having other protective groups in the sugar radical with (1) a compound of Formula VI to form initially a compound of Formula V or (2) with a compound of Formula VII: to form an N-(6)-acyl derivative which is reduced with lithium aluminium hydride. 2<SP>1</SP>,3<SP>1</SP>,5<SP>1</SP> - Tri - O - acetyl - N(6) - (3 - phenylnorcamphenyl - 2) - adenosine derivatives may be obtained by reacting (1) 1 - (2<SP>1</SP>,3<SP>1</SP>,5<SP>1</SP> - tri - O- acetyl - D - ribofuranosyl) - 4 - cyano - imidazol- 5-amine with ortho-formic acid triethyl ester and cyclizing the product in the presence of an amine of Formula III, or (2) reacting 4-(3-phenylnorcamphenyl  -  2 - amino) - 6 - [2<SP>1</SP>,3<SP>1</SP>,5<SP>1</SP> - O- acetyl - D - ribofuranosyl - 1 - amino] pyrimidin- 5-amine with methyl formate. N(6)-(3-phenylnorcamphenyl-2) adenine is reacted with 2,3,5- tri-O-acetyl ribofuranosyl chloride in the presence of hexamethyldisilazane or with 1,2,3,5- tetra - O - acetyl - D - ribofuranose in the presence of an acid catalyst (p-toluene sulphonic acid) to obtain N(6)-(3-phenyl-norcamphenyl-2)- adenosine derivatives having protective groups in the sugar radical. Compounds of Formula (I) increase coronary flow, increase the partial pressure of oxygen in the venous blood, inhibit lipolysis and/or reduce cholesterol levels; they are also active in an intravascular pain model. Compounds of Formula I form with a physiologically acceptable carrier, a pharmaceutical preparation which may be administered orally, parenterally or rectally.